The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy

The first-line standard of care for patients with metastatic colorectal cancer (mCRC) is FOLFIRI (irinotecan, levo-leucovorin, 5-fluorouracil (5-FU)) plus bevacizumab. With the renewed interest in cancer immunotherapy with agents such as vaccines, checkpoint inhibitors and immune modulators, the pos...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncoimmunology
Main Authors: Roselli, Mario, Formica, Vincenzo, Cereda, Vittore, Jochems, Caroline, Richards, Jacob, Grenga, Italia, Orlandi, Augusto, Ferroni, Patrizia, Guadagni, Fiorella, Schlom, Jeffrey
Formato: Artigo
Idioma:Inglês
Publicado: Taylor & Francis 2016
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5006891/
https://ncbi.nlm.nih.gov/pubmed/27622042
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2016.1188243
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares